Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma enrolled in the Republic of Korea: KEYNOTE-859.

被引：0
作者：
Rha, Sun Young
Lee, Jeeyun
Ryu, Min-Hee
Yin, Lina
Leconte, Pierre
Bhagia, Pooja
Oh, Do-Youn
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol,Yonsei Canc Ctr, Seoul, South Korea
[2] Samsung Med Ctr, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Merck & Co Inc, Rahway, NJ USA
[5] MSD France, Puteaux La Defense, France
[6] Seoul Natl Univ, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.428
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：428 / 428
页数：1
相关论文
共 50 条
[11]   Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system [J].
Lang, Wenwang ;
Deng, Lian ;
Lu, Meijun ;
Ouyang, Ming .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) :1027-1042
[12]   KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma [J].
Tabernero, Josep ;
Bang, Yung-Jue ;
Van Cutsem, Eric ;
Fuchs, Charles S. ;
Janjigian, Yelena Yuriy ;
Bhagia, Pooja ;
Li, Kan ;
Adelberg, David ;
Qin, Shu Kui .
FUTURE ONCOLOGY, 2021, 17 (22) :2847-2855
[13]   KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1-selected populations [J].
Rha, Sun Young ;
Wyrwicz, Lucjan ;
Weber, Patricio Eduardo Yanez ;
Bai, Yuxian ;
Ryu, Min-Hee ;
Lee, Jeeyun ;
Rivera, Fernando ;
Alves, Gustavo Vasconcelos ;
Garrido, Marcelo ;
Shiu, Kai-Keen ;
Fernandez, Manuel Gonzalez ;
Li, Jin ;
Lowery, Maeve Aine ;
Cil, Timucin ;
Cruz, Felipe Melo ;
Qin, Shukui ;
Yin, Lina ;
Bordia, Sonal ;
Bhagia, Pooja ;
Oh, Do-Youn .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[14]   Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma [J].
Xu, Rui-hua ;
Arkenau, Hendrik-Tobias ;
Bang, Yung-Jue ;
Denlinger, Crystal S. ;
Kato, Ken ;
Tabernero, Josep ;
Wang, Jin ;
Li, Jiang ;
Castro, Henry ;
Moehler, Markus H. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[15]   Benmelstobart plus anlotinib and chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2 study [J].
Bie, Liangyu ;
Wei, Chen ;
Luo, Suxia ;
Dong, Shuailei ;
Gu, Zhiwei ;
Ma, Yijie ;
Xia, Qingxin ;
Zhang, He ;
Li, Jing ;
Deng, Wenying ;
Li, Ning .
CELL REPORTS MEDICINE, 2025, 6 (06)
[16]   Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062 [J].
Satake, Hironaga ;
Lee, Keun-Wook ;
Chung, Hyun Cheol ;
Lee, Jeeyun ;
Yamaguchi, Kensei ;
Chen, Jen-Shi ;
Yoshikawa, Takaki ;
Amagai, Kenji ;
Yeh, Kun-Huei ;
Goto, Masahiro ;
Chao, Yee ;
Lam, Ka-On ;
Han, Shi Rong ;
Shiratori, Shinichi ;
Shah, Sukrut ;
Shitara, Kohei .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (03) :221-229
[17]   Health-related quality of life (hrqol) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma [J].
Lowery, M. ;
Wyrwicz, L. ;
Oh, D-Y. ;
Shiu, K. K. ;
Weber, P. Yanez ;
Bai, Y. ;
Lee, J. ;
Rivera, F. ;
Alves, G. ;
Garrido, M. ;
Fernandez, M. Gonzalez ;
Li, J. ;
Cil, T. ;
Cruz, F. ;
Qin, S. ;
Yin, L. ;
Valderrama, A. ;
Bordia, S. ;
Rha, S. Y. .
ANNALS OF ONCOLOGY, 2023, 34 :S854-S855
[18]   Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. [J].
Tabernero, Josep ;
Van Cutsem, Eric ;
Bang, Yung-Jue ;
Fuchs, Charles S. ;
Wyrwicz, Lucjan ;
Lee, Keun Wook ;
Kudaba, Iveta ;
Garrido, Marcelo ;
Chung, Hyun Cheol ;
Salguero, Hugo Raul Castro ;
Mansoor, Wasat ;
Braghiroli, Maria Ignez Freitas Melro ;
Goekkurt, Eray ;
Chao, Joseph ;
Wainberg, Zev A. ;
Kher, Uma ;
Shah, Sukrut ;
Kang, SoonMo Peter ;
Shitara, Kohei .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
[19]   KEYNOTE-585: randomized, phase 3 study of chemotherapy plus pembrolizumab vs chemotherapy plus placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer [J].
Bang, Yung-Jue ;
Van Cutsem, Eric ;
Fuchs, Charles ;
Ohtsu, Atsushi ;
Tabernero, Josep ;
Ilson, David ;
Hyung, Woo Jin ;
Strong, Vivian ;
Goetze, Thorsten ;
Yoshikawa, Takaki ;
Tang, Laura ;
Sun, Linda ;
Hasan, Aisha ;
Koshiji, Minori ;
Shitara, Kohei .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[20]   Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer. [J].
Yin, Xianli ;
Zhang, Yun ;
Deng, Yanhong ;
Xu, Nong ;
Xu, Jianming ;
Li, Lei ;
Song, Xiaotong ;
Lu, Haolan ;
Gong, John ;
Liu, Dongfang .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345